Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI
Abstract Challenges remain for clinicians over balancing the efficacy of active antithrombotic therapy and simultaneous bleeding reduction in patients. The clinical data of 347 patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) were retrospectively analyz...
Main Authors: | Yong-zhe Guo, Zi-wen Zhao, Shu-mei Li, Liang-long Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-08-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-96606-y |
Similar Items
-
Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI
by: Aniket Puri, et al.
Published: (2013-03-01) -
High bolus tirofiban vs abciximab in acute STEMI patients undergoing primary PCI - The tamip study
by: Mohammed A Balghith
Published: (2012-01-01) -
Intracoronary versus intravenous administration of tirofiban during percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients
by: S. Pradhan, et al.
Published: (2015-12-01) -
Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke.
by: John-Ih Lee, et al.
Published: (2017-01-01) -
The influence of tirofiban on the troponin, brain natriuretic peptide, heart function in patients with Acute Myocardial Infarction after PCI
by: Zi-Xiang Chen
Published: (2017-02-01)